Respiratory syncytial virus (RSV) is the most common cause of respiratory tract infections and hospitalization among infants around the world. There is currently no way to predict which infants will develop severe RSV illness.
This program supports clinicians in recognizing the significant burden of RSV, diagnosing RSV illness in clinical practice, and identifying RSV seasonality. This program will also discuss strategies for RSV prophylaxis in infants.
This program has received financial support from Sanofi in the form of an unrestricted educational grant.